| Scleroderma Clinical Trials (MAIN MENU) | |
|
| Scleroderma Clinical Trials: Current Studies, Open Enrollments |
|
|
| Overview of Scleroderma Clinical Trials and Treatments |
| Systemic Scleroderma Symptoms. At present, there are no proven treatments or cure for any forms of scleroderma. However, there are effective therapies for many of the symptoms as well as clinical trials for specific scleroderma related symptoms. ISN. (Also see: What is Scleroderma and Types of Scleroderma) |
| |
| Treatment of complications associated with systemic sclerosis. Systemic sclerosis is characterized by various circulatory, dermatological, gastrointestinal, musculoskeletal, pulmonary, and renal complications. Although there is no cure for systemic sclerosis, management of its associated complications can help improve patients' quality of life. (PubMed) Am J Health Syst Pharm. 2008 Feb 15; 65(4):315-21. |
| AIMSPRO for Systemic Sclerosis |
| AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis. To study the safety and tolerability of a hyperimmune goat serum product (AIMSPRO) in the treatment of systemic sclerosis (SSc) through a period of 26 weeks of study participation. The secondary objective of the study is to assess the efficacy of AIMSPRO as a therapeutic agent for SSc using inter alia the SSc-HAQ questionnaire and the modified Rodnan skin score. ClinicalTrials.gov. |
| Sypharma - Press Release. Australia’s Sypharma, a privately owned company will be supplying an aseptically manufactured biological (AIMSPRO) for clinical trials in Europe. AIMSPRO is an injectable hyperimmune caprine serum derivative. Two clinical trials with AIMSPRO address late stage Scleroderma (Diffuse Sclerosis) and Bladder Dysfunction in Secondary Progressive Multiple Sclerosis. BioInternational Corporation. 6/11/08. |
| Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis |
| |
| Ambrisentan for Digital Ulcers |
| A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma). A Pilot Study to Evaluate the Efficacy of Ambrisentan in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis. This study is currently recruiting participants. ClinicalTrials.gov. |
| Atherosclerosis in Scleroderma |
| Premature Coronary Atherosclerosis in Scleroderma. The purpose of this trial is to study the proportion of scleroderma patients who suffer from asymptomatic coronary atherosclerosis compared to healthy controls. This study is currently recruiting participants. clinicaltrials.gov, May, 2009. (Also see: Atherosclerosis) |
| ASTIS Study |
| ASTIS Study: High Dose Immunoablation and Hematopoietic Stem cell Transplantation versus Monthly Intravenous Pulse Therapy Cyclophosphomide in Severe Systemic Sclerosis. ISN. |
| Bosentan, Tracleer |
| Bosentan (Tracleer) appears to be beneficial for a variety of scleroderma symptoms, such as digital ulcers, pulmonary fibrosis, pulmonary hypertension, and skin fibrosis. ISN. |
| |
| Combination Therapies |
| Severe Systemic Sclerosis - Combination Therapy Study (05-070T). A Randomized, Open-Label, Phase II/III Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation with Auto-CD34+HPC versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis. Presently Recruiting. Feinstein Institute for Medical Research. |
| Cyclophosphamide (Cytoxan ®) and Revimmune |
| Current Studies, Initial Results Positive |
| Cyclophosphamide (Cytoxan) and Revimmune for Scleroderma Lung Disease. Clinical trial and research information on cyclophosphamide for pulmonary alveolitis. ISN. |
|
|
| Cyclophosphamide and rATG with Hematopoietic Stem Cell Support |
| Cyclophosphamide and rATG With Hematopoietic Stem Cell Support Clinical Trial. To evaluate the efficacy (phase II) of two treatment modalities: pulse cyclophosphamide versus high dose cyclophosphamide and rATG (rabbit antithymocyte globulins) rescued with autologous peripheral blood stem cell transplant (PBSCT). Currently recruiting. Northwestern University. ClinicalTrials.gov. Contact information: d-spahovic@northwestern.edu and tel 1-312-908-0059. |
| Journal Publications by Richard K. Burt, M.D. Division of Immunotherapy. Northwestern University, Chicago, Illinois. |
| DETECT (Screening for PH) |
| Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc) (DETECT). A two-stage prospective observational cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension. This study is currently recruiting participants. Verified by Actelion, October 2008. ClinicalTrials.gov. (Also see: Pulmonary Hypertension) |
| Dasatinib |
| Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis. The purpose of this study is to see if dasatinib, with its known side effects, is safe to use in patients with scleroderma pulmonary fibrosis. This study is currently recruiting participants. Clinicaltrials.gov. August 2009. (Also see: Pulmonary Fibrosis) |
| DISTOL-1 |
| Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine (DISTOL-1). This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Principal Investigator: James Seibold, MD. Started May 2009. ClinicalTrials.gov. (Also see: Digital Ulcers) |
| Fludarabine and Donor Peripheral SCT |
| Fludarabine and Total-Body Irradiation Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis. This phase II trial is studying how well giving fludarabine together with total-body irradiation followed by a donor peripheral stem cell transplant works in treating patients with severe systemic sclerosis. Clinical Trials.gov 04/02/09. |
| Imatinib Mesylate (Gleevec) |
| Current Studies, Open Enrollment, Initial Results Positive, 2008 |
| Imatinib Mesylate (Gleevec) Clinical Trials for Systemic Scleroderma. Imatinib mesylate (Gleevec) is currently used for certain forms of leukemia, and is now in the following clinical trials for safety and efficacy for systemic scleroderma. ISN. |
| Pulmonary Fibrosis with Systemic Sclerosis |
| Open Enrollment, 2008 |
| Recruiting is taking place for a multi-center placebo controlled research study for pulmonary fibrosis with systemic sclerosis sponsored by Novartis Pharmaceuticals. Male and female patients, 18 to 65 years of age may be eligible for participation. |
| Interested patients can contact the Medical College of Wisconsin (414-456-7019), University of Houston (713-500-7118), UCLA (310-825-4744), Boston University (617-638-4344) or at John Hopkins University (410-550-8582) in Baltimore, Maryland. Novartis Pharmaceuticals. Posted 01-04-08. (Also see: Pulmonary Fibrosis and What is Scleroderma?) |
| Riociguat (BAY63-2521) |
| A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) (Patent-1). The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH). This study is currently recruiting participants. clinicaltrials.gov. |
| Bayer Schering Pharma Presents Positive Results Of Phase II Study With Riociguat. Results from the multi-center, open-label, uncontrolled phase II trial, showed that riociguat significantly improved exercise capacity from baseline values in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Medical News Today. 05/21/09. (Also see: PAH) |
| Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Riociguat is currently being investigated in phase III clinical trials for the oral treatment of PH after promising results in phase II trials. J Mittendorf. National Institutes of Health PubMed. May 2009 (Also see: PAH) |
| Scleroderma Lung Study II |
| Scleroderma Lung Study II follows Scleroderma Lung Study I, a clinical research study that compared the efficacy and toxicity of daily oral cyclophosphamide (CYC, also called CytoxanTM) with a daily placebo pill for the treatment of scleroderma-related lung fibrosis. |
| Scleroderma Lung Study II. This study compares 2 different medications—daily oral cyclophosphamide (CYC, also called CytoxanTM) with daily oral mycophenolate mofetil (MMF, also called CellceptTM) in the treatment of scleroderma-related pulmonary fibrosis. There are twelve study centers across the U.S. This study is currently recruiting. University of California, Los Angeles. November 2009. (Also see: Pulmonary Fibrosis, Cellcept, and Cytoxan) |
| SCOT Trial |
| Open Enrollment, 2005-2008 |
| SCOT Clinical Trial, which stands for "Scleroderma Cyclophosphamide Or Transplantation", will compare two potential therapies: autologous stem cell transplantation versus high-dose monthly cyclophosphamide. Study dates 2005-2008. (Also see: Cyclophosphamide, Cytoxan and Stem Cell Transfusion) |
| TV Video: Hannah - Health Insurance Story. View her fight for insurance coverage for the SCOT Trial, with David Becker, ISN Assistant News Guide. Posted 11-16-09. (Also see: Patient Rights, and David Becker) |
| Scleroderma Patient Experiences: SCOT Trial on You Tube. A short film documenting the experiences of several patients undergoing experimental treatment for scleroderma. It also includes physician interviews which provide information on the SCOT study and advances in research. Duke Clinical Research, 11-17-08. |
| High Dose Cyclophosphamide (CYC) Without Stem Cell Transplantation in Systemic Sclerosis. High dose CYC without stem cell transplantation leads to rapid improvement of the modified Rodnan skin, HAQ, and PGA scores in the severe early diffuse SSc. Christopher V. Tehlirian. 689 ACR 2006. (Also see: Cytoxan, ASTIS Clinical Trial, and Skin Fibrosis) |
| Sildenafil Citrate (Viagra) for Pulmonary Hypertension |
| Continuing Studies, Positive Results |
| Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease. SLx-2101 is a novel, long-acting PDE-5 inhibitor being developed for the management of diseases associated with vascular dysfunction such as Raynaud's. The company has also completed four Phase 2a clinical studies in hypertension, Raynaud's disease and erectile dysfunction, all of which further demonstrated the efficacy of the compound. Surface Logix Inc. 2008. (Also see: Raynaud's Treatments) |
| (Also see: Pulmonary Hypertension) |
| Stem Cell Transplants for Scleroderma |
| Continuing Studies, Open Entrollment |
| Stem Cell Transplants (Bone Marrow Transplants) for Early Diffuse Scleroderma. ISN. |
| |
| Twins and Siblings With and Without Autoimmune Diseases |
| Open Enrollment (A 5-year study) |
 Families with Twins or Siblings where one has Systemic Rheumatic Disorders (Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Lupus, Scleroderma, or Myositis) and one does not. The goal of study 03-E-0099 is to assess why one twin or sibling developed disease and why the other brother or sister did not.
The siblings may or may not be twins, but must be of the same gender and be within a 3-year age difference. Biological parents, or, in some cases, children, will also be included in the study.
Families may enroll at the NIH Clinical Center in Bethesda, Maryland, just 9 miles north of Washington, DC or at their local physician’s office. Transportation assistance may be available and there is no charge for study-related evaluations and medical tests.
For information on the study, call the NIH patient recruiting office toll free at 1-800-411-1222 (For TTY: 1-866-411-1010). National Institutes of Health Clinical Center (NIH). 11/25/05. (Also see: Scleroderma Research Registries and Causes of Scleroderma: Genetics) |
| See Also |
Sjögren's Treatments & Clinical Trials
Scleroderma Medical News
Scleroderma Symptoms (treatments are listed for each symptom) |
